In the last few years, the pharmaceutical landscape in Germany has been transformed by a class of drugs understood as GLP-1 receptor agonists. Originally developed to handle Type 2 diabetes, these medications have gotten worldwide attention for their profound efficacy in weight management. In Germany, where metabolic health concerns are on the increase, the intro and guideline of medications like Ozempic, Wegovy, and Mounjaro have triggered significant medical and public interest.

This post provides an in-depth exploration of GLP-1 medications within the German healthcare system, covering their mechanisms, accessibility, costs, and the regulative framework governing their usage.

What Are GLP-1 Receptor Agonists?

Glucagon-like peptide-1 (GLP-1) is a naturally happening hormone produced in the intestinal tracts. It plays an important role in glucose metabolic process and hunger policy. GLP-1 receptor agonists are synthetic variations of this hormone developed to last longer in the body.

The primary functions of these medications consist of:

• Insulin Stimulation: They trigger the pancreas to release insulin when blood sugar level levels are high.
• Glucagon Suppression: They prevent the liver from releasing too much sugar into the blood stream.
• Stomach Emptying: They decrease the rate at which food leaves the stomach, causing prolonged satiety.
• Hunger Regulation: They act upon the brain's appetite centers to minimize yearnings and general caloric consumption.

Key GLP-1 Medications Available in Germany

Numerous GLP-1 medications have been approved by the European Medicines Agency (EMA) and are currently readily available through the German pharmaceutical market. While some are strictly for diabetes, others are particularly identified for persistent weight management.

Comparison Table of Common GLP-1 Medications

Brand name Name

Active Ingredient

Primary Indication in Germany

Administration

Ozempic

Semaglutide

Type 2 Diabetes

Weekly Injection

Wegovy

Semaglutide

Obesity/ Weight Management

Weekly Injection

Mounjaro

Tirzepatide

Diabetes & & Weight Management

Weekly Injection

Rybelsus

Semaglutide

Type 2 Diabetes

Daily Oral Pill

Saxenda

Liraglutide

Obesity/ Weight Management

Daily Injection

Trulicity

Dulaglutide

Type 2 Diabetes

Weekly Injection

The Regulatory Framework and Supply Challenges

In Germany, the Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte – BfArM) supervises the security and circulation of these drugs. Due to the huge rise in demand driven by social media and global patterns, Germany— like many other countries— has actually dealt with substantial supply shortages.

To protect patients with Type 2 diabetes, BfArM and different German medical associations have actually released standards. These guidelines prompt doctors to prioritize Ozempic for diabetic patients and discourage its “off-label” use for weight-loss, recommending that weight-loss patients transition to Wegovy, which is specifically produced for that purpose.

Supply Chain Realities:

1. Export Bans: At different points, German authorities have actually thought about or carried out constraints on exporting these drugs to make sure domestic supply.
2. Stringent Prescription Monitoring: Pharmacies are motivated to confirm that prescriptions for Ozempic are tied to a diabetes medical diagnosis.
3. Production Increases: Manufacturers like Novo Nordisk and Eli Lilly are presently investing billions in European production facilities (including websites in Germany) to meet the need.

Expenses and Insurance Coverage (Krankenkasse)

The German health care system is divided into Statutory Health Insurance (Gesetzliche Krankenversicherung – GKV) and Private Health Insurance (Private Krankenversicherung – PKV). The protection for GLP-1 medications depends mostly on the medical diagnosis.

Statutory Health Insurance (GKV)

• For Diabetes: If a patient is detected with Type 2 diabetes, the GKV usually covers the cost of GLP-1 medications (like Ozempic or Rybelsus). The patient typically just pays a little co-payment (Zuzahlung) of EUR5 to EUR10.
• For Obesity: Historically, German law (SGB V § 34) classifies weight-loss medications as “way of life drugs,” implying the GKV is restricted from covering them. Regardless of Hier klicken of Wegovy, many statutory patients should pay the full retail rate expense.

Private Health Insurance (PKV)

• Coverage differs significantly in between companies and private plans. Lots of private insurance providers will cover the expense if the doctor can show medical necessity (e.g., a BMI over 30 with comorbidities like high blood pressure).

Out-of-Pocket Costs

For those paying independently, Wegovy can cost between EUR170 and EUR300 each month, depending upon the dose. Mounjaro follows a comparable prices structure.

The Process of Obtaining a Prescription in Germany

Acquiring GLP-1 medication in Germany follows a rigorous medical procedure. These are not “non-prescription” drugs and need professional supervision.

1. Preliminary Consultation: A client should seek advice from a General Practitioner (Hausarzt) or an Endocrinologist.
2. Diagnostic Tests: Blood tests are needed to examine HbA1c levels (for diabetes) and kidney/liver function.
3. Eligibility Assessment: For weight loss, the German Obesity Society (DAG) recommends a BMI of 30+ or 27+ with weight-related health issues.
4. Prescription Issuance: The physician problems either a “Pink Bill” (Kassenrezept for GKV diabetes clients) or a “Blue/White Bill” (Privatrezept for private pay or weight-loss).
5. Follow-up: Regular monitoring is required to handle adverse effects and change does incrementally (titration).

Side Effects and Safety Considerations

While extremely reliable, GLP-1 medications are not without dangers. German scientific standards emphasize that these drugs ought to become part of a holistic approach including diet and workout.

Common Side Effects include:

• Nausea and vomiting (especially during the first couple of weeks).
• Diarrhea or constipation.
• Abdominal pain and bloating.
• Heartburn/Acid reflux.

Unusual but Serious Risks:

• Pancreatitis.
• Gallstones.
• Potential threat of thyroid C-cell growths (observed in animal studies; human risk is still being kept track of).
• Kidney disability due to dehydration from intestinal concerns.

The Future of GLP-1 in Germany

Germany is placing itself as a hub for both the consumption and production of metabolic treatments. The current statement of Eli Lilly's new plant in Alzey, Rhineland-Palatinate, highlights the strategic importance of this sector. Additionally, there is ongoing political dispute relating to whether the GKV must upgrade its policies to cover weight problems medication, acknowledging obesity as a chronic illness instead of a lifestyle choice.

Often Asked Questions (FAQ)

1. Is Ozempic offered for weight-loss in Germany?

While Ozempic includes semaglutide, it is just formally approved in Germany for Type 2 diabetes. Using it for weight reduction is considered “off-label.” Website besuchen is the variation specifically approved and marketed for weight-loss.

2. Can I get GLP-1 medications through telemedicine in Germany?

Yes, particular qualified telemedicine platforms in Germany can issue private prescriptions after a digital consultation and a review of the patient's medical history. Nevertheless, the client must still pay the full cost for the medication at the drug store.

3. Why is there a scarcity of these drugs?

The lack is mainly due to extraordinary international demand. The production process for the injection pens is complicated and has had a hard time to equal the millions of new prescriptions released worldwide.

4. What is the difference between Ozempic and Mounjaro?

Ozempic (Semaglutide) imitates one hormonal agent (GLP-1). Mounjaro (Tirzepatide) is a dual-agonist, mimicking both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide), which may lead to even greater weight reduction results in some clients.

5. Do I have to take this medication permanently?

Scientific studies recommend that lots of clients gain back weight when the medication is ceased. In Germany, doctors usually view these as long-lasting treatments for chronic conditions, though some clients may successfully preserve weight reduction through considerable way of life modifications.

GLP-1 medications represent a significant leap forward in the treatment of metabolic illness in Germany. While difficulties such as high costs for self-payers and supply chain instabilities remain, the healing advantages for those with diabetes and obesity are indisputable. As the medical community continues to improve its understanding of these drugs, and as production capacity boosts, GLP-1 therapy is set to remain a cornerstone of German metabolic medicine for the foreseeable decade.

The landscape of metabolic health and weight management has actually undergone an advanced shift over the last years, mostly driven by the advent of GLP-1 (Glucagon-Like Peptide-1) receptor agonists. In Website , medications such as Ozempic, Wegovy, and Mounjaro have transitioned from specific niche diabetic treatments to mainstream medical subjects. However, the German health care system's unique structure— defined by the interplay between statutory health insurance coverage (GKV), private health insurance coverage (PKV), and stringent pharmaceutical price regulations— develops a complicated environment for clients looking for these therapies.

This article offers a thorough analysis of the expenses, protection policies, and restorative landscape of GLP-1 agonists in Germany.

• * *

Understanding GLP-1 Therapy

GLP-1 receptor agonists are a class of medications that imitate the natural GLP-1 hormonal agent produced in the gut. These drugs serve two main functions: they promote insulin secretion in action to high blood sugar level and sluggish gastric emptying, which increases the feeling of satiety (fullness).

In Germany, these medications are strictly “rezeptpflichtig” (prescription-only). They are authorized for two main indications:

1. Type 2 Diabetes Mellitus: To enhance glycemic control.
2. Weight problems Management: For clients with a BMI over 30, or over 27 with weight-related comorbidities (e.g., high blood pressure).

• * *

Comparison of GLP-1 Medications and Costs in Germany

The rate of pharmaceutical items in Germany is controlled by the Arzneimittelpreisverordnung (Drug Price Ordinance). This ensures that the cost of a specific brand remains fairly consistent across all “Apotheken” (drug stores) in the country.

Table 1: Estimated Costs of Popular GLP-1 Medications (2024 Estimates)

Medication

Active Ingredient

Frequency

Main Indication

Approximate. Expense per Pack (Self-Pay)

Ozempic

Semaglutide

Weekly

Type 2 Diabetes

EUR80— EUR90 (1 pen/1 month)

Wegovy

Semaglutide

Weekly

Obesity/Weight Loss

EUR170— EUR300 (Depends on dosage)

Mounjaro

Tirzepatide

Weekly

Diabetes/ Obesity

EUR260— EUR330 (Monthly supply)

Rybelsus

Semaglutide

Daily (Oral)

Type 2 Diabetes

EUR100— EUR120 (30 tablets)

Saxenda

Liraglutide

Daily

Obesity

EUR290— EUR310 (5 pens/30 days)

Victoza

Liraglutide

Daily

Type 2 Diabetes

EUR120— EUR150 (2-pen pack)

Note: Prices undergo change based on dose increases and existing pharmaceutical market changes.

• * *

Statutory vs. Private Health Insurance Coverage

Among the most considerable elements affecting the cost of GLP-1 therapy in Germany is the patient's insurance status and the “Indikation” (medical reason) for the prescription.

Statutory Health Insurance (Gesetzliche Krankenversicherung – GKV)

For the approximately 90% of the German population covered by GKV, the expense depends entirely on whether the drug is prescribed for diabetes or weight reduction.

• Type 2 Diabetes: If a physician problems a “Kassenrezept” (pink prescription), the insurance covers the bulk of the expense. The patient only pays a “Zuzahlung” (co-payment), which is generally EUR5 to EUR10 per pack.
• Obesity/Weight Loss: Under present German law ( § 34 SGB V), medications used mainly for weight loss are categorized as “Life-Style-Arzneimittel.” Consequently, statutory insurers are typically prohibited from covering these costs. Clients must get a “Privatrezept” (blue/white prescription) and pay the complete list price out of pocket.

Private Health Insurance (Private Krankenversicherung – PKV)

Private insurance companies use more flexibility, however protection is not ensured.

• Reimbursement: Most PKV plans cover GLP-1 treatment for Type 2 Diabetes.

• Obesity: For weight loss, some private insurance companies have actually started covering Wegovy or Mounjaro, offered the patient fulfills specific medical criteria (e.g., a BMI > > 30 and recorded failure of conservative weight-loss methods). Clients typically pay in advance and submit the invoice for compensation.

• • *

Aspects Influencing the Total Cost of Treatment

While the rate of the medication is the main expenditure, other elements contribute to the overall monetary commitment of GLP-1 therapy in Germany:

1. Dose Escalation: Most GLP-1 therapies (like Wegovy) require a gradual increase in dose over several months to lessen adverse effects. Higher doses of certain brand names might bring a greater cost.
2. Medical Consultation Fees: Private patients and self-payers must spend for the medical professional's time. According to the Gebührenordnung für Ärzte (GOÄ), a consultation and physical test can range from EUR30 to EUR100.
3. Laboratory Tests: Routine blood work to keep an eye on HbA1c levels, kidney function, and pancreatic enzymes is necessary, adding to the total cost.
4. Supply Chain Issues: While the cost is managed, supply scarcities have actually periodically required patients to look for alternative brand names or smaller sized pack sizes, which can be less cost-efficient in time.

• * *

The “Lifestyle Drug” Legal Debate

The classification of GLP-1 agonists as “way of life drugs” is a point of substantial contention in the German medical neighborhood.

Why the distinction exists:

• Historical Context: The law was initially developed to omit drugs for hair loss or erectile dysfunction from public funding.
• Budgetary Concerns: With millions of Germans qualifying as overweight, the GKV-Spitzenverband (National Association of Statutory Health Insurance Funds) fears that covering weight-loss drugs would cause a monetary crisis for the insurance coverage system.

• Progressing Perspectives: Many medical associations argue that obesity is a persistent disease, not a lifestyle choice, and that the long-lasting cost savings (less strokes, cardiac arrest, and joints replacements) would exceed the expense of the medication.

• • *

Benefits and Side Effects of GLP-1 Therapy

Before committing to the long-lasting expenses, patients must know the scientific profile of these medications.

Typical Benefits:

• Significant Weight Reduction: Clinical trials for Wegovy revealed an average weight-loss of roughly 15%.
• Cardiovascular Protection: Many GLP-1 agonists have actually been shown to minimize the threat of major adverse cardiovascular occasions (MACE).
• Blood Glucose Regulation: Highly efficient at lowering HbA1c levels in diabetics.
• Cravings Control: Directly impacts brain centers responsible for food cravings.

Typical Side Effects:

• Gastrointestinal Issues: Nausea, throwing up, and diarrhea are the most frequently reported side impacts.
• Pancreatitis: A rare but serious threat.
• Gallstones: Increased threat related to rapid weight loss.

• Muscle Loss: Without sufficient protein intake and resistance training, users might lose substantial lean muscle mass.

• • *

Summary Checklist for Patients in Germany

If a citizen in Germany is considering GLP-1 treatment, the following steps are generally needed:

1. Consult a Specialist: Visit a Diabetologist or an Internist specializing in metabolic health.
2. Identify Diagnosis: Confirm if the prescription is for Type 2 Diabetes or Obesity.
3. Verify Insurance Type: Check with the insurance company (specifically if PKV) to see if they reimburse weight-loss medications.
4. Confirm Availability: Call regional pharmacies to make sure the recommended dosage is in stock, as supply scarcities persist.
5. Spending plan for Self-Payment: If prescribed for weight-loss without diabetes, anticipate a monthly expenditure of EUR170 to EUR330.

• * *

Regularly Asked Questions (FAQ)

1. Is Ozempic cheaper in Germany than in the USA?

Yes, substantially. Due to federal government cost controls through the Arzneimittelpreisverordnung, Ozempic expenses roughly EUR80— EUR90 each month in Germany, whereas prices in the USA can exceed ₤ 900 for the same supply.

2. Can I get a GLP-1 prescription through a Telehealth provider in Germany?

Yes, specific licensed German telehealth platforms can release personal prescriptions for GLP-1 medications following a digital consultation. Nevertheless, these are practically exclusively “Privatrezept” (self-pay).

3. Does the cost of Wegovy reduction with higher doses?

No, the expense normally increases as the dose increases. In Germany, the maintenance dose (2.4 mg) of Wegovy is notably more costly than the starting dosages (0.25 mg).

4. Will my Krankenkasse (GKV) ever spend for Wegovy?

Currently, statutory health insurance does not cover Wegovy for weight-loss. However, there are ongoing political discussions regarding exceptions for clients with severe morbid obesity (BMI > > 35 or 40) who have failed all other treatments.

5. Are there “generic” versions of GLP-1 drugs readily available in German drug stores?

Not yet. The patents for semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro) are still active. Liraglutide (Saxenda) patents are nearing expiration, which may lead to cheaper generics in the coming years.

• * *

GLP-1 therapy represents an effective tool in the battle against metabolic disease, but its expense in Germany stays a hurdle for numerous. While those with Type 2 Diabetes take advantage of the robust support of statutory health insurance coverage, clients having problem with obesity currently face a “self-pay” barrier. As GLP-1-Lieferanten in Deutschland continues to mount concerning the long-lasting health advantages of these drugs, the German health care system might ultimately be forced to re-evaluate its “lifestyle” classification to make sure broader access to these life-altering treatments.

The worldwide pharmaceutical landscape has been changed recently by the development of GLP-1 (Glucagon-like peptide-1) receptor agonists. Originally developed to manage Type 2 diabetes, these medications— including home names like Ozempic and Wegovy— have actually gained worldwide popularity for their efficacy in persistent weight management.

In Germany, a country understood for its extensive health care guidelines and thorough social security system, the cost and accessibility of these drugs are topics of considerable public interest. This short article checks out the monetary intricacies of GLP-1 medications in Germany, examining how insurance coverage structures, federal government guidelines, and particular drug brand names influence the last price a client pays at the drug store.

The Regulatory Framework: How Prices Are Set in Germany

Unlike the United States, where pharmaceutical pricing is mainly market-driven, Germany uses a highly managed system to control drug costs. The German healthcare system is divided mostly into Statutory Health Insurance (Gesetzliche Krankenversicherung or GKV) and Private Health Insurance (Private Krankenversicherung or PKV).

The rate of any prescription drug in Germany is affected by the AMNOG (Arzneimittelmarktneuordnungsgesetz), a law enacted in 2011. This legislation needs pharmaceutical companies to show the “added advantage” of a brand-new drug compared to existing treatments. Based on this examination, the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband) works out a compensation price with the maker.

The Role of Prescription Types

In Germany, the color of the prescription identifies who bears the expense:

• Red Prescription: For those with public insurance coverage (GKV). Many of the expense is covered, with the patient paying a small co-payment (usually EUR5 to EUR10).
• Blue Prescription: Usually for independently insured clients or “off-label” use. The patient pays the full pharmacy price and looks for compensation from their private insurance provider afterward.
• Green Prescription: A recommendation from a doctor for non-prescription or self-pay products.

GLP-1 Medications for Diabetes vs. Obesity

An important distinction in the German market is the indicator for which the GLP-1 is prescribed. Presently, German law separates strictly in between “clinically needed” treatments for chronic diseases like diabetes and “lifestyle” medications, which typically include weight-loss treatments.

1. Treatment for Type 2 Diabetes

When a GLP-1 like Ozempic or Victoza is recommended for Type 2 diabetes, it is classified as a needed medical intervention. For GLP-1-Kosten in Deutschland of Germans covered by public health insurance, this implies the insurer covers the bulk of the expense. The patient only pays the standard co-payment.

2. Treatment for Obesity and Weight Loss

The scenario changes considerably for weight-loss. Under Section 34 of the Social Code Book V (SGB V), medications aimed mainly at weight reduction or “improvement of life quality” are excluded from reimbursement by the statutory health insurance coverage. This means that even if a drug like Wegovy is authorized for obesity, public insurance coverage funds are presently prohibited from paying for it. Clients need to usually pay the complete market price expense.

Breakdown of GLP-1 Costs in Germany

The expense of GLP-1 medications differs depending on the brand name, dose, and whether the drug is being bought for diabetes or weight management.

Estimated Pricing Table (Pharmacy Retail Prices)

The following table supplies a summary of the estimated monthly expenses for popular GLP-1 medications in Germany for self-paying clients (since mid-2024).

Drug Name

Active Ingredient

Main Indication

Estimated Monthly Cost (Self-Pay)

Ozempic

Semaglutide

Type 2 Diabetes

EUR80— EUR90 (0.5 mg/1mg)

Wegovy

Semaglutide

Obesity/Weight Loss

EUR170— EUR300 (Dose reliant)

Mounjaro

Tirzepatide

Diabetes/ Obesity

EUR260— EUR330

Rybelsus

Semaglutide (Oral)

Type 2 Diabetes

EUR100— EUR140

Victoza

Liraglutide

Type 2 Diabetes

EUR120— EUR150

Saxenda

Liraglutide

Obesity/Weight Loss

EUR200— EUR250

Keep in mind: Prices undergo change based upon pharmacy markups and upgraded manufacturer agreements.

Factors Influencing the Price

A number of elements add to why GLP-1 costs in Germany are structured the method they are:

1. Fixed Pharmacy Pricing: Germany has a fixed price system for prescription drugs (Arzneimittelpreisverordnung). This prevents drug stores from completing on price, guaranteeing that a drug costs the very same throughout the nation.
2. Dosage Escalation: For drugs like Wegovy and Mounjaro, the rate typically increases as the dose boosts. Patients generally start on a low “starter dose” and titrate up, suggesting the regular monthly expenditure grows over the very first few months of treatment.
3. Supply and Demand: While Germany has cost controls, worldwide shortages have impacted availability. While this doesn't usually spike the main rate, it may lead patients to seek alternative, more pricey formulations or brands if their main choice is out of stock.

Comparing Germany to Other Markets

Germany remains among the more affordable Western markets for GLP-1 medications, especially when compared to the United States. In the U.S., the list price for Wegovy can surpass ₤ 1,300 each month. On the other hand, even the greatest self-pay cost in Germany seldom surpasses EUR350. This is mostly due to the cumulative bargaining power of the European health care systems and the earnings margin caps put on German pharmacies and wholesalers.

Insurance coverage Reimbursement: A Changing Landscape?

The argument over whether public health insurance coverage must cover weight loss medications is ongoing in Germany. Medical associations argue that obesity is a persistent disease that causes costly secondary conditions like cardiovascular disease and joint failure.

• Present Status: For now, the “lifestyle drug” exemption stays in location for GKV patients.
• Possible Changes: There are discussions in the Federal Joint Committee (G-BA) relating to exceptions for clients with a really high BMI and existing comorbidities, however a broad policy shift has not yet occurred.
• Private Insurance (PKV): Private insurance companies have more flexibility. Some PKV providers might cover Wegovy or Mounjaro for weight reduction if it is deemed “clinically necessary,” though this typically requires a detailed application and a physician's validation.

Practical Considerations for Patients in Germany

For individuals in Germany thinking about GLP-1 treatment, the following steps are typically included:

1. Consultation: An assessment with a GP or endocrinologist is compulsory, as these are prescription-only drugs.
2. Blood Work: Doctors will usually inspect HbA1c levels, kidney function, and thyroid health.
3. Prescription Issuance: If recommended for diabetes, a red prescription is released. If for weight-loss, a blue or white prescription (personal) is issued.
4. Pharmacy Purchase: The patient provides the prescription at any regional drug store. If it is a self-pay scenario, the patient pays the total at the counter.

Germany offers a structured and fairly transparent pricing design for GLP-1 medications. While diabetic clients gain from extensive protection under the statutory health insurance system, those looking for these medications for weight management face substantial out-of-pocket expenses due to historical “way of life” classifications. Regardless of these hurdles, the controlled drug store costs in Germany remain substantially lower than in lots of other parts of the world, making these innovative treatments available to a larger section of the population than in simply market-driven systems.

• * *

FREQUENTLY ASKED QUESTION: GLP-1 Cost and Availability in Germany

1. Can I get Ozempic for weight reduction in Germany?

Ozempic is particularly authorized for Type 2 Diabetes. While physicians can technically prescribe it “off-label” for weight loss, they are significantly discouraged from doing so due to provide lacks for diabetic patients. For weight-loss, medical professionals are encouraged to recommend Wegovy, which contains the very same active ingredient however is approved for obesity.

2. Why is Wegovy more costly than Ozempic?

Although both contain Semaglutide, Wegovy is marketed and packaged particularly for weight-loss at different dosages. Due to the fact that Wegovy is categorized as a weight-loss drug, it does not fall under the exact same compensation rate negotiations as diabetes medications, causing a greater retail cost for the customer.

3. Does German public health insurance coverage cover Mounjaro?

Mounjaro (Tirzepatide) is covered by public insurance for the treatment of Type 2 Diabetes. Nevertheless, like Wegovy, if it is recommended specifically for weight management, it is normally not covered by the GKV, and the patient must pay the complete rate.

4. Are there less expensive generic versions of GLP-1 drugs in Germany?

Presently, there are no generic versions of Semaglutide (Ozempic/Wegovy) or Tirzepatide (Mounjaro) in Germany, as these drugs are still under patent protection. Clients must rely on the brand-name items from Novo Nordisk and Eli Lilly.

5. Will the price of GLP-1 drugs decrease in the future?

Costs might reduce as more recent rivals go into the market and as makers increase production capacity. Additionally, if the German federal government reclassifies weight problems as an illness that necessitates compensated medication, the “expense” to the specific client in the public system would drop to an easy co-payment.